ANNX
Annexon, Inc. Health Care Pharmaceutical Preparations Russell 3000
$4.05Close
$604.9MMarket cap
$2.68 – $6.9652-week range
Nov 9, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 18 · weaker than 82% of stocks over 12 months
- Far from its high 42% below its 52-week high
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
42%
1wk
up 8.0%
price change
1mo
down 4.3%
price change
12-month return
up 38%
market up 11% ·
its own up 16%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.9×
price / book
Earnings yield
down 48.9%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 82%
return on equity
Free cash margin
—
-$186.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.1%
$0.25 a day · 2×ATR $3.55
RS
18 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.72
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 1 of 8
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 36.6% over the year, from 109m to 149m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 12, 2026
Results reaction
Aug 12, 2026-2% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$63.5M | -$130.7M | -$145.6M | -$143.7M | -$154.1M | -$216.4M |
| Net income | -$63.4M | -$130.3M | -$141.9M | -$134.2M | -$138.2M | -$206.7M |
| Earnings per share | — | -$3.40 | -$2.60 | -$1.77 | -$1.01 | -$1.33 |
| Free cash flow | -$53.6M | -$107.8M | -$122.8M | -$121.3M | -$118.0M | -$186.5M |
| Cash | $268.6M | $74.8M | $140.0M | $225.1M | $49.5M | $162.1M |
| Shareholders' equity | $344.3M | $231.9M | $231.2M | $250.6M | $293.1M | $211.6M |
| Shares outstanding | 38.16m | 38.56m | 47.72m | 78.37m | 109.38m | 149.36m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 12, 2026 | Quarterly ↗ | Jun 30, 2026 | 43d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 30, 2026 | Annual ↗ | Dec 31, 2025 | 89d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 14, 2025 | Quarterly ↗ | Jun 30, 2025 | 45d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Mar 26, 2024 | Annual ↗ | Dec 31, 2023 | 86d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 12, 2026 | Results · Other events ↗ |
| Aug 10, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 6, 2026 | Other events ↗ |
| Jul 30, 2026 | Material agreement · New obligation · Other events ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 30, 2026 | Results ↗ |
| Feb 17, 2026 | Director or officer change ↗ |
| Jan 14, 2026 | Regulation FD ↗ |
| Jan 12, 2026 | Other events ↗ |
| Nov 14, 2025 | Material agreement · Other events ↗ |
| Nov 10, 2025 | Results ↗ |